NASDAQ:MGNX

MacroGenics Q3 2026 Earnings Results & Report

MacroGenics logo
$1.92 -0.05 (-2.28%)
As of 02:46 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MacroGenics was expected to report Q3 2026 earnings on November 12, 2026, after market closes. Analysts expected earnings of -$0.3151 per share on revenue of $39.18 million. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available.

Earnings Announcement Details

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
7:00 AM ET

MacroGenics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.3151
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

MacroGenics Revenue Results

Actual Revenue
N/A
Expected Revenue
$39.18 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

MacroGenics Earnings Headlines

MacroGenics (NASDAQ:MGNX) Cut to Sell at Wall Street Zen
MacroGenics, Inc. (NASDAQ:MGNX) Stock Now Rated "Hold" by Sell-Side Brokerages
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
See More MacroGenics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MacroGenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MacroGenics and other key companies, straight to your email.

About MacroGenics

MacroGenics (NASDAQ:MGNX) is a biotechnology company focused on discovering and developing antibody-based medicines, primarily for cancer. Founded in 2000 and headquartered in Rockville, Maryland, the company works on its own drug candidates and collaborates with other pharmaceutical and biotechnology companies.

Its research uses antibody-engineering technologies, including platforms designed to engage immune cells against tumors and to deliver therapeutic payloads to cancer cells. MacroGenics’ portfolio has included margetuximab, marketed as Margenza, an antibody treatment approved in the United States for certain patients with HER2-positive metastatic breast cancer.

The company’s development programs and collaborations span multiple regions, with partners involved in advancing or commercializing therapies in international markets. MacroGenics continues to focus on developing antibody-based treatments for cancer.

View MacroGenics Profile